News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC – João Alessi
Photo from João Alessi/Twitter
Jul 19, 2023, 18:03

Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC – João Alessi

Glad to share our paper recently published in Nature. In which, we report the impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC. Collaboration b/w Dana-Farber and Memorial Sloan Kettering Radiation Oncology.

For article: Click here

Source: João Alessi/Twitter

cancer Dana-Farber Durvalumab João Alessi Memorial Sloan Kettering Radiation Oncology OncoDaily Oncology pneumonitis
Special Coverage
Blog
Oct 5, 2024, 10:56
Carnell Jermaine Hampton: FMEA technique to investigate and improve the approach to Total Body Irradiation
Blog
Oct 5, 2024, 10:53
Chris Chukwunyere: Sharing Insights on Community-Based Participatory Research at the PRECISE Symposium
Blog
Oct 5, 2024, 10:39
Anna-Elina Rahikainen: Thank you IPOS for the opportunity to present
Blog
Oct 5, 2024, 09:50
Jashodeep Datta Named Principal Investigator for $2.5M NCI R37 MERIT Grant
Blog
Oct 5, 2024, 09:30
Medicaid expansion increased use of adjuvant therapy for NSCLC
Insight
Oct 5, 2024, 09:27
Patricia P. Falconer: Patients residing in rural communities have more barriers to care and a higher risk of financial toxicity
Blog
Oct 5, 2024, 09:26
Emily Holthuis: Expanding Partnerships with Patients and Carers in the EORTC
Blog
Oct 5, 2024, 09:24
Andreas Brandl: Prophylactic use of HIPEC in T4 colorectal cancer at ESSO43
Blog
Oct 5, 2024, 09:22
Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma
Insight
Oct 5, 2024, 09:20
DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO
Blog
Oct 5, 2024, 09:17
Mark Lawler: Economist Impact taking money from Big Tobacco while running heath conferences
Blog
Oct 5, 2024, 09:16
Jame Abraham: Shlomo Koyfman appointed as the Director of Precision Oncology Program at Cleveland Clinic